Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Complete Response Seen with This Type of Lymphoma

Leuk Lymphoma; ePub 2016 Sep 21; de la Fuente, et al

Publish date:: September 28, 2016

Dural lymphoma is an indolent tumor with long survival, according to a retrospective review involving 23 individuals.

All participants had dural lymphoma. 13 received focal radiotherapy, 6 whole brain radiotherapy, 3 chemotherapy-alone, and 1 chemotherapy followed by whole brain radiotherapy. Among the results:

• 1 patient achieved partial response; the remainder responded completely.

• 4 patients relapsed (2 with local and 2 with systemic disease).

• At a median follow-up of ~5 years, 9 in every 10 achieved progression-free survival, and all patients were alive at last follow-up.

The authors concluded that complete response with focal therapy is attainable, but long-term follow-up is needed to monitor for relapse.

Citation: de la Fuente M, Haggiagi A, Moul A, et al. Marginal zone dural lymphoma: The Memorial Sloan Kettering Cancer Center and University of Miami experiences. [Published online ahead of print September 21, 2016]. Leuk Lymphoma. doi:10.1080/10428194.2016.1218006.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Indolent Lymphoma

Follicular lymphoma treatment can benefit patients 80 years and older,

Survival Data Reported From Largest CAR T Trial in B-Cell Lymphoma,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

R2 appears active in high-risk FL and MZL,

In situ vaccination produced responses in indolent NHL,